First in class therapeutic intervention in solid tumors: Development of YB-800R1, a radio labeled mAb targeting NPTXR

Research unit

INNOSUISSE

Project number

121.049 IP-LS

Project title

First in class therapeutic intervention in solid tumors: Development of YB-800R1, a radio labeled mAb targeting NPTXR

Texts for this project

	German	French	Italian	English
Key words	-	-	-
Abstract	-	-	-

Category	Text
Key words (English)	Life sciences, Human medicine
Abstract (English)	Ymmunobio is a biotech firm developing GI cancer therapies targeting the Neuronal Pentraxin Receptor (NPTXR), found in 70-80% of metastatic gastric and colorectal cancers. Their lead product, YB-800, a humanized antibody, is advanced in collaboration with PSI, aiming for clinical proof of concept.